Abstract
Recent experimental data suggest that immunity can be activated to prevent tumors. The rationale for prevention is strong because the setting is one endowed with an immune system that is neither impaired by tumor and treatment-induced suppression, nor tolerant to tumor-associated antigens. Oncogenic growth factor receptors are tumor antigens and rational targets for specific immunoprevention. Successful prevention of mammary carcinomas in Her-2/neu transgenic mice is cited as an evidence of the validity of this approach. The specific properties of the Her-2/neu gene product as an antigen and the nature of the immune responses induced by effective preventive treatments are summarized.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
